Optimistic Buy Rating for Biohaven Ltd. Driven by Regulatory Progress and Market Potential of Troriluzole

William Blair analyst Myles Minter has maintained their bullish stance on BHVN stock, giving a Buy rating on August 19.

Myles Minter has given his Buy rating due to a combination of factors surrounding Biohaven Ltd.’s regulatory progress and potential market impact. The company’s recent filing indicates that the FDA no longer requires an advisory committee meeting for the regulatory decision on troriluzole in spinocerebellar ataxia (SCA), which suggests a streamlined path towards approval. This development is seen as a positive indicator, enhancing the likelihood of regulatory success.
Minter also highlights the favorable risk/benefit profile of troriluzole, especially given the lack of approved therapies for SCA. Despite missing the primary endpoint in Phase III trials, the data shows a significant slowing in disease progression, which could be compelling for regulatory approval if the FDA is satisfied with the quality of the supporting studies. These factors, combined with the potential for market differentiation, underpin Minter’s optimistic outlook on Biohaven’s stock.

In another report released on August 19, BTIG also maintained a Buy rating on the stock with a $60.00 price target.